Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
RedHill Biopharma Ltd. develops and commercializes specialty biopharmaceutical products focused on gastrointestinal diseases, infectious diseases and oncology. Its recurring news includes U.S. commercialization activity for Talicia, an FDA-approved all-in-one rifabutin-based therapy for H. pylori infection, as well as updates on joint commercialization through Talicia Holdings Inc.
Company updates also cover clinical and preclinical development across RedHill’s pipeline, including RHB-204 for MAP-related Crohn’s disease research, RHB-102 (Bekinda) for gastrointestinal and oncology-support indications, and opaganib in oncology models and related clinical research. Additional recurring themes include regulatory disclosures, intellectual property, capital-structure matters, governance actions and operating or financial results for the foreign issuer’s ADSs.
RedHill Biopharma (NASDAQ:CPIX) closed a private placement of 8,571,429 ADSs (or equivalents) plus series A-1 and A-2 warrants at a combined $0.70 per ADS. The deal provides about $6 million gross upfront, with up to $13.4 million additional potential proceeds from warrant exercises.
According to RedHill, funds are expected to support near-term liquidity and a possible acquisition of commercial-stage, revenue-generating pharmaceutical assets, though no definitive agreement exists and there is no assurance any acquisition or warrant exercise will occur.
RedHill Biopharma (CPIX) entered a definitive agreement for a private placement of 8,571,429 ADSs (or equivalents) plus series A-1 and A-2 warrants at a combined price of $0.70 per ADS. Gross proceeds are expected to be about $6 million, with up to $13.4 million more if all warrants are exercised.
The deal is expected to close on June 22, 2026. According to RedHill, proceeds will fund a potential strategic product acquisition and support working capital, R&D and general corporate purposes.
RedHill Biopharma (ticker: CPIX) announced that the FDA granted rare pediatric disease designation to opaganib for treating neuroblastoma, in addition to existing orphan drug designation.
Benefits may include a Priority Review Voucher, potential seven years' marketing exclusivity, fee waivers, tax credits and accelerated review, if approved.
RedHill Biopharma (Nasdaq:CPIX) has begun recognition and enforcement proceedings in Korea for a New York Supreme Court final judgment against Kukbo totaling about $10.9 million.
The judgment, including roughly $8.9 million principal and $1.95 million legal fees with 9% interest, is final and no longer appealable.
RedHill Biopharma (NASDAQ:CPIX) is pursuing collaborations, including with the WHO SOLIDARITY CORE platform, to clinically evaluate opaganib as a potential Ebola virus disease (EVD) treatment, targeting the Bundibugyo ebolavirus subtype.
According to RedHill, opaganib has Phase 3 antiviral data in severe COVID-19 and preclinical Ebola activity, but remains investigational and unapproved.
RedHill (CPIX) reported in vitro data showing its next-generation oral candidate RHB-204 demonstrates MAP killing comparable to RHB-104, achieved in spot and phage assays and using lower doses of two active ingredients. A Phase 2 trial in MAP-positive Crohn's disease patients is planned, with non-dilutive funding sought and multiple regulatory designations and patent protection through 2041.
RedHill Biopharma (Nasdaq: RDHL) reported full-year 2025 results and operational highlights on April 27, 2026, citing strategic transactions, commercial progress for Talicia and focused R&D activity. Key items include a $4.0M Cumberland investment into Talicia Holdings, Talicia U.S. net revenues of ~$8.9M, ex-U.S. revenues of ~$1.9M, a RHB-102 licensing deal worth up to $60M in milestones, a final $10.5M New York Supreme Court judgment in RedHill's favor, year-end cash of $4.1M and positive equity of $4.3M.
RedHill (Nasdaq: RDHL) presented independent preclinical data at AACR 2026 showing that opaganib may enhance chemotherapy efficacy in high‑risk neuroblastoma and augment STING‑mediated anti‑tumor immunity in triple‑negative breast cancer (TNBC).
Penn State and Apogee data indicate opaganib destabilized n‑Myc and increased ceramide‑driven apoptosis with OXDOX; University of Kansas data show opaganib plus low‑dose diABZI potentiated STING effects in TNBC. Opaganib holds FDA Orphan and Rare Pediatric Disease designations for neuroblastoma.
H. pylori infections market (CPIX) is projected to expand from a USD 270 million market in 2025 at a 9.4% CAGR through 2036 across the 6MM. US holds ~85% of 2025 revenue and ~57 million diagnosed prevalent cases; emerging therapies such as rifasutenizol, linaprazan glurate, and tegoprazan are expected to reshape treatment paradigms with reported Phase III eradication rates >90% for some candidates.
Challenges include a limited pipeline, geographic regulatory gaps, rising antibiotic resistance, and adherence issues with high pill burdens.
RedHill (Nasdaq:RDHL) and Cumberland (Nasdaq:CPIX) have begun the full U.S. sales and operational launch of Talicia under Talicia Holdings Inc. (THI), a 70/30 RedHill/Cumberland joint operating entity. Cumberland made a $4 million strategic investment and the joint model launched after an October 2025 agreement.
Talicia is positioned as the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy, is patent-protected through 2042, holds eight years of U.S. market exclusivity (QIDP), and targets an estimated 1.6 million U.S. patients treated annually.